A KEY SECTOR

The company is dedicated to the continued development of innovative technologies and products that bring innovative solutions to the market. To support this vision, the combination of S.M.B.’s highly qualified personnel and heavy investments have led S.M.B. to be one of the most completely equipped pharmaceutical companies in Europe in terms of both analytical & galenical high technology equipment and also one of the most competitive in Drug Delivery Systems.

Our drug delivery capabilities focus on developing solutions for patients mainly with improved formulations, new dosage forms and new galenical formulations, which require high scientific and technological know-how.

S.M.B. concentrates its R&D activites and strategies on :

• FORMULATIONS WITH HIGHER BIOAVAILIBILITY, which use less active ingredient for the same or superior therapeutic effect.
  e.g. : Lidose® 
   
• ONCE-A-DAY FORMULATIONS,
  which prolong the active ingredient's activity to provide treatment coverage of the patient over a 24 hour period.
   
•  DRY POWDER INHALER FORMULATIONS,
  which can achieve a higher lung deposition in comparison to reference products.
   
• EFFERVESCENT TABLETS,
  SMB has more than 35 years of experience in this area and continues to invest to improve the quality of its products, offering a large portfolio of formulations.
   
• NEW COMBINATIONS OF ACTIVE INGREDIENTS

RESULT: IMPROVEMENT IN SAFETY AND INCREASE IN COMPLIANCE,
The use of S.M.B. technologies and products provides important benefits for the patient.

PATENTS

Part of the R&D Department is based in Brussels and is in permanent contact with several Belgian universities. It forms a key component of S.M.B. current technology and future strategies. In 1999, a new R&D center (Galephar M/F) was build in Marche-en-Famenne (Wallonia) while keeping some initial development activities in Brussels.
Our scientific expertise includes :

•  Galenical formulations (microgranules, semi-solid, ...)
•  Analytical (DSC, dissolution tests, ...)
•  Bioanalytical (4 LC/MS/MS, ...)
•  Regulatory
•  Intellectual property
•  Clinical (PK, Phase II, Phase III, ...)
•  Analytical methods development

We are specialized in the development, production and packaging of solid dosage forms. Our know-how covers both immediate and extended-release formulations. Our portfolio includes not only generics but also generic plus and new combinations of active ingredients.